ETF Holdings Breakdown of ALT

Stock Name	Altitude Group Plc
Ticker	ALT(GBX) LSE
TYPE	Common Stock
Country	UK
ISIN	GB00B0LSFV82
LEI	213800VACSTYYSI39R89

ALT institutional holdings

The adjusted close for ALT on 2025-11-12 was 4.23

The following institutional investment holdings of ALT have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-12 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 54,827 USD 231,918 4.23

2025-11-12 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 54,827 0.3% USD 231,918 -0.9% 4.23

Total = 109,654 USD 463,836
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	54,827	USD 231,918	4.23
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	54,827 0.3%	USD 231,918 -0.9%	4.23
Total =	109,654	USD 463,836

News associated with ALT

Analysts Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $17.40: Shares of Altimmune, Inc. (NASDAQ:ALT – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation […] - 2025-09-17 02:26:48
Martin Roy Varley Acquires 85,000 Shares of Altitude Group (LON:ALT) Stock: Altitude Group plc (LON:ALT – Get Free Report) insider Martin Roy Varley bought 85,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The stock was purchased at an average price of GBX 23 per share, for a total transaction of £19,550. Martin Roy Varley also recently made the following […] - 2025-09-12 02:36:42
Insider Buying: Altitude Group (LON:ALT) Insider Buys 20,000 Shares of Stock: Altitude Group plc (LON:ALT – Get Free Report) insider Martin Roy Varley acquired 20,000 shares of the company’s stock in a transaction dated Friday, September 5th. The stock was acquired at an average cost of GBX 23 per share, with a total value of £4,600. Martin Roy Varley also recently made the following trade(s): On […] - 2025-09-09 02:05:04
Altimmune (NASDAQ:ALT) Earns Buy Rating from HC Wainwright: Altimmune (NASDAQ:ALT – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $12.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 226.09% from the stock’s current price. A number of other […] - 2025-08-15 02:50:47
Federated Hermes Inc. Buys Shares of 187,727 Altimmune, Inc. (NASDAQ:ALT): Federated Hermes Inc. purchased a new position in Altimmune, Inc. (NASDAQ:ALT – Free Report) in the first quarter, Holdings Channel reports. The institutional investor purchased 187,727 shares of the company’s stock, valued at approximately $939,000. Other hedge funds also recently made changes to their positions in the company. Ameriprise Financial Inc. lifted its holdings in […] - 2025-08-07 04:31:00
Analysts Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $19.00: Altimmune, Inc. (NASDAQ:ALT – Get Free Report) has been given an average rating of “Buy” by the six ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. […] - 2025-07-04 02:22:59
Pre-Market Most Active for Jun 26, 2025 : ALT, TSLL, NVDA, GLNG, SRFM, BBAI, SQQQ, MU, NIO, CRCL, QS, JPM: The NASDAQ 100 Pre-Market Indicator is up 95.31 to 22,333.05. The total Pre-Market volume is currently 155,943,518 shares traded.The following are the most active stocks for the pre-market session: Altimmune, Inc. (ALT) is -4.56 at $3.15, with 21,157,349 shares traded. As report - 2025-06-26 09:29:54
Altimmune Announces Positive Topline Data From IMPACT Phase 2b Study Of Pemvidutide In MASH: (RTTNews) - Altimmune, Inc. (ALT) Thursday announced positive topline results from the IMPACT Phase 2b study of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). The study met its primary goal. - 2025-06-26 08:44:39
Altitude Group (LON:ALT) Stock Crosses Above 200-Day Moving Average – Time to Sell?: Altitude Group plc (LON:ALT – Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 24.31 ($0.33) and traded as high as GBX 25 ($0.34). Altitude Group shares last traded at GBX 24.55 ($0.34), with a volume of 1,387 shares trading hands. […] - 2025-06-26 04:50:54
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Altimmune, Inc. (NASDAQ:ALT): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 16.6% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 92,392 shares of the company’s stock after buying an additional 13,126 shares during the quarter. UBS AM a distinct […] - 2025-06-12 04:46:44
Bank of America Corp DE Increases Stake in Altimmune, Inc. (NASDAQ:ALT): Bank of America Corp DE raised its holdings in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 21.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 181,889 shares of the company’s stock after acquiring an additional 32,382 shares during the quarter. Bank […] - 2025-06-06 04:34:53
Altimmune, Inc. (NASDAQ:ALT) Shares Bought by Northern Trust Corp: Northern Trust Corp lifted its position in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 5.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 665,916 shares of the company’s stock after buying an additional 35,918 shares during the period. Northern Trust Corp’s […] - 2025-05-22 04:58:50
Baird Financial Group Inc. Takes $429,000 Position in Altimmune, Inc. (NASDAQ:ALT): Baird Financial Group Inc. acquired a new stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 59,440 shares of the company’s stock, valued at approximately $429,000. Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. […] - 2025-05-16 05:31:14
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of “Buy” by Brokerages: Altimmune, Inc. (NASDAQ:ALT – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-05-12 03:10:56
Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by MetLife Investment Management LLC: MetLife Investment Management LLC increased its stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 7.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 44,474 shares of the company’s stock after purchasing an additional 2,897 shares during the period. MetLife Investment Management LLC’s holdings in Altimmune were worth $321,000 as of […] - 2025-05-08 05:02:49
Barclays PLC Grows Position in Altimmune, Inc. (NASDAQ:ALT): Barclays PLC lifted its position in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 1.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 157,528 shares of the company’s stock after purchasing an additional 1,787 shares during the quarter. Barclays PLC’s holdings in Altimmune were worth […] - 2025-05-05 04:48:49
Noteworthy Friday Option Activity: ALT, DUOL, AMD: Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Altimmune Inc (Symbol: ALT), where a total of 15,292 contracts have traded so far, representing approximately 1.5 million underlying shares. That amounts to about 74.3% - 2025-05-02 16:22:38
Legal & General Group Plc Lowers Position in Altimmune, Inc. (NASDAQ:ALT): Legal & General Group Plc decreased its stake in Altimmune, Inc. (NASDAQ:ALT – Free Report) by 8.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 68,102 shares of the company’s stock after selling 6,046 shares during the period. Legal & General Group Plc’s holdings in Altimmune were worth $491,000 as of its most […] - 2025-04-30 05:30:58
Schroder Investment Management Group Has $3.14 Million Stock Position in Altimmune, Inc. (NASDAQ:ALT): Schroder Investment Management Group lessened its position in Altimmune, Inc. (NASDAQ:ALT – Free Report) by 9.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 428,321 shares of the company’s stock after selling 45,544 shares during the period. Schroder Investment Management Group owned approximately 0.60% of Altimmune worth […] - 2025-04-06 05:34:53
Nichole Stella Buys 50,000 Shares of Altitude Group plc (LON:ALT) Stock: Altitude Group plc (LON:ALT – Get Free Report) insider Nichole Stella purchased 50,000 shares of the business’s stock in a transaction on Monday, March 31st. The shares were bought at an average price of GBX 26 ($0.34) per share, for a total transaction of £13,000 ($16,880.92). Altitude Group Stock Performance ALT opened at GBX 25.25 […] - 2025-04-03 02:24:59
Sequoia Financial Advisors LLC Acquires 3,500 Shares of Altimmune, Inc. (NASDAQ:ALT): Sequoia Financial Advisors LLC grew its stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 34.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 13,655 shares of the company’s stock after purchasing an additional 3,500 shares during the period. Sequoia Financial Advisors LLC’s holdings […] - 2025-03-21 06:24:59
Noteworthy Friday Option Activity: DXC, ALT, MSFT: Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in DXC Technology Co (Symbol: DXC), where a total volume of 15,294 contracts has been traded thus far today, a contract volume which is representative of approximat - 2025-03-14 17:20:35
Rhumbline Advisers Has $756,000 Stake in Altimmune, Inc. (NASDAQ:ALT): Rhumbline Advisers lowered its stake in Altimmune, Inc. (NASDAQ:ALT – Free Report) by 4.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 104,876 shares of the company’s stock after selling 4,343 shares during the quarter. Rhumbline Advisers’ holdings in Altimmune were worth […] - 2025-03-07 07:22:50
Altimmune, Inc. (NASDAQ:ALT) Stock Position Decreased by Los Angeles Capital Management LLC: Los Angeles Capital Management LLC cut its stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 53.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,197 shares of the company’s stock after selling 35,340 shares during the period. Los Angeles Capital Management […] - 2025-03-05 08:41:41
Altimmune (NASDAQ:ALT) Given “Buy” Rating at HC Wainwright: Altimmune (NASDAQ:ALT – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $12.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 101.34% from the stock’s previous close. A number of other research […] - 2025-03-05 04:56:51
Altimmune, Inc. (NASDAQ:ALT) Sees Large Decline in Short Interest: Altimmune, Inc. (NASDAQ:ALT – Get Free Report) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 23,320,000 shares, a decrease of 5.2% from the January 15th total of 24,590,000 shares. Based on an average daily trading volume, of 3,190,000 shares, the short-interest ratio is currently 7.3 […] - 2025-02-19 06:46:12
Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $20.83: Altimmune, Inc. (NASDAQ:ALT – Get Free Report) has been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. […] - 2025-02-04 04:46:59

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.